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Although tuberculosis poses a significant health threat to the 
global population, it is a challenge to develop new and effec-
tive therapeutic strategies. Nitric oxide (NO) and inducible 
NO synthase (iNOS) are important in innate immune re-
sponses to various intracellular bacterial infections, including 
mycobacterial infections. It is generally recognized that re-
active nitrogen intermediates play an effective role in host 
defense mechanisms against tuberculosis. In a murine model 
of tuberculosis, NO plays a crucial role in antimycobacterial 
activity; however, it is controversial whether NO is critically 
involved in host defense against Mycobacterium tuber-
culosis in humans. Here, we review the roles of NO in host 
defense against murine and human tuberculosis. We also dis-
cuss the specific roles of NO in the central nervous system 
and lung epithelial cells during mycobacterial infection. A 
greater understanding of these defense mechanisms in hu-
man tuberculosis will aid in the development of new strat-
egies for the treatment of disease.
[Immune Network 2009;9(2):46-52]
INTRODUCTION
Tuberculosis (TB) is a bacterial infectious disease caused by 
the  obligate  human  pathogen  Mycobacterium  tuberculosis 
(MTB). TB remains an urgent global health problem, with a 
third of the global population latently infected and eight mil-
lion new cases each year. Although only 5∼10% of infected 
individuals develop active TB, the fatality rate is nearly two 
million people annually  (1-3). Following  exposure to MTB, 
a series of immune responses are triggered that ultimately de-
fine  the  course  of  the  infection  (4,5).  The  pathogenesis  of 
infection is complicated; however, recent discoveries have at-
tracted great attention due to their association with host-de-
rived and microbial factors. Advances in free radical research 
have revealed that the production of reactive oxygen and ni-
trogen oxide species such as superoxide (O2
−) and nitric ox-
ide (NO) by innate immune cells is a relatively effective host 
defense mechanism against bacterial, viral, parasitic, and fun-
gal  infections  (5,6).
    The host cells that are protective against TB include macro-
phages, dendritic cells, T lymphocytes, and alveolar epithelial 
cells (2,3,7). Macrophages are believed to play a pivotal role 
i n  t h e  i m m u n e  r e s p o n s e  a g a i n s t  m y c o b a c t e r i a  t h r o u g h  t h e  
production of cytokines such as tumor necrosis factor (TNF)-
α  and interleukin (IL)-1β . TNF-α  and IL-1β , along with in-
terferon (IFN)-γ , which is produced by T lymphocytes, can 
induce NO production in macrophages via the action of in-
ducible forms of the enzyme NO synthase (iNOS) (8-10). NO 
and  related  reactive  nitrogen  intermediates  (RNI)s  can  kill 
and/or  inhibit  intracellular  pathogens  such  as  mycobacteria 
(11-14). The actions of iNOS and the production of NO corre-
late well with antimycobacterial defense in murine models of 
TB infection (10,12,15). Although it has been demonstrated 
t h a t  i N O S  e x p r e s s i o n  i s  u p - r e g ulated  in  macrophages  from 
human TB lesions (16), few reports have examined the anti-
mycobacterial effects of cytokines and NO released by human 
macrophages (17,18). These data suggest that human macro-
phages possess a NO-independent antimicrobial mechanism, 
although  a  role  for  NO  in  human  host  defense  cannot  be 
excluded.
    MTB  infects  the  airways  and  stimulates  alveolar  macro-
phages, epithelial cells, and macrophages. As a result, NO is 
produced in response to the stimulation of cytokines and che-
mokines (19). By producing NO, alveolar epithelial cells can 
actively  participate  in  alveolar  inflammatory  processes  and Nitric Oxide in Mycobacterial Infection
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Figure 1. Yang et al. Synthesis, regulation, and anti- 
mycobacterial function of NO in mycobacterial infec-
tion. Activated inducible nitric oxide synthase (iNOS) 
produces N
ω-OH-L-arginine from L-arginine, and then 
N
ω-OH-L-arginine is transduced to form NO and L- 
citruline. Synthesis of NO and reactive nitrogen oxides
(RNI) are positively regulated by Th1 cytokines, whereas
they are negatively regulated by Th2 cytokines. Pro-
duced NO and RNIs, which combined with NO and 
O2
－, can directly kill intracellular MTB in the infected
cells (including macrophages, epithelial and glial 
cells), although the action of NO is dependent on the
species and specific cell types.
defense mechanisms against MTB. In this review, we discuss 
the role of NO in defense mechanisms against MTB and the 
mechanisms regulating the production of NO in macrophages, 
including  microglia  and  alveolar  epithelial  cells.
OVERVIEW OF NO PRODUCTION AND FUNCTION
NO is a gaseous free radical molecule with pleiotropic func-
tions in pathophysiology that is synthesized by a two-step en-
zymatic  reaction  involving  a  monooxygenase  (12,13).  One 
molecule of L-arginine is oxidized at the terminal nitrogen in 
guanidine  to  produce  N
ω-OH-L-arginine  as  an  intermediate. 
This intermediate is then further oxidized to form one mole-
cule each of NO and L-citrulline (13,14). L-arginine (a condi-
t i o n a l l y  e s s e n t i a l  a m i n o  a c i d )  i s  o b t a i n e d  f r o m  e x o g e n o u s  
(food) and endogenous sources, including whole-body pro-
tein  degradation  and,  to  a  lesser  extent,  de  novo s y n t h e s i s 
from citrulline by renal arginosuccinate synthase (20,21). Two 
sequential reactions are catalyzed by NOSs, resulting in the 
constitutive  expression  of  enzymes  primarily  in  endothelial 
cells (eNOS) and neuronal cells (nNOS), and as an inducible 
isoform (iNOS). Constitutively produced NOSs contribute to 
several physiological processes including vasorelaxation and 
neurotransmission. In contrast, iNOS is expressed in various 
cells including macrophages, neutrophils, epithelial cells, and 
hepatocytes, and it produces excessive NO during infection, 
inflammation, and states of physiological stimulation (22-24).
  Th1 cytokines such as IFN-γ , IL-1β , and TNF-α  stimulate 
the expression of macrophage iNOS, leading to NO produc-
tion. In contrast, under the influence of Th2 cytokines such 
as  IL-4,  IL-10,  and  IL-13,  arginine  is  depleted  by  arginases 
(8-10). NO is one of several RNIs with antimicrobial activity 
(18,25). The increase in RNIs is mediated through reactive ni-
trogen oxides (e.g., peroxynitrite (ONOO
－)) generated by the 
reaction of NO with O2
－ (13,24) (Fig. 1). NO and RNIs can 
modify  bacterial  DNA,  proteins,  and  lipids  in  both  the  mi-
crobe and host. NO can also deaminate and directly damage 
b a c t e r i a l  D N A  b y  g e n e r a t i n g  a b asic  sites  and  strand  breaks 
(7). Other potential killing mechanisms by NO include inter-
actions  with  accessory  protein  targets  such  as  iron-sulfur 
groups, heme groups, thiols, aromatic or phenolic residues, 
tyrosyl radicals, and amines. These reactions result in enzy-Nitric Oxide in Mycobacterial Infection
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matic  inactivation  and/or  other  protein  malfunctions  (26).
THE ROLE OF NO IN HOST DEFENSE AGAINST 
MICROBIAL INFECTIONS
During infection with Mycobacterium, Salmonella, Streptococ-
cus, Leishmania, or Bordetella, excessive NO is produced af-
ter the induction of iNOS. In many cases, excessive NO pro-
duction results in innate resistance to bacterial infection. In 
a  study  of  Bordetella  pertussis  infection  in  wild-type  (WT) 
and iNOS-knockout (iNOS KO) mice, the iNOS KO mice dis-
played  increased  bacterial  growth  and  susceptibility  to  in-
fection as compared with the WT mice (27). In a study of 
murine salmonellosis (Salmonella typhimurium), the use of a 
NO inhibitor, N
ω-monomethyl-L-arginine (L-NMMA), or iNOS 
KO mice led to similar antimicrobial effects (12,28). In these 
studies, the lack of NO production was associated with ex-
tensive  damage,  including  increased  bacterial  growth,  in-
creased apoptosis, and the exacerbation of histopathological 
characteristics in mouse livers infected with Salmonella enter-
ica s e r o v a r  T y p h i m u r i u m  ( 1 2 ) .  A l t h o u g h  N O  s h o w s  a n t i -
microbial activity against bacteria, fungi, and parasites, some 
studies suggest dual functions during viral infection. NO pro-
duced  by  macrophages  and  phagocytic  cells  can  act  as  an 
effector  molecule  during  innate  host  defense  mechanisms. 
For example, NO shows antiviral activity in response to cer-
tain viruses such as coxsackievirus (29-31), Epstein-Barr virus 
(32), and herpes simplex virus (HSV)-1 (33-35). In contrast 
t o  t h e  a n t i b a c t e r i a l  a c t i v i t y  o b s e r v e d  w i t h  N O ,  t h i s  a n t i v i r a l 
activity  is  associated  with  nonspecific  damage  to  host  cells 
and tissues, leading to an exacerbation of viral pathogenesis 
in many infections such as influenza (36), tick-born virus (37), 
sendai virus (38), HSV-1 (39,40), and cytomegalovirus (41,42). 
Therefore, despite the antiviral activity of NO, excessive NO 
production may facilitate viral pathogenesis. These dual func-
tions  of  NO  may  lead  to  differential  outcomes  during  viral 
infection. 
THE ROLE OF NO IN MYCOBACTERIAL 
INFECTION: MURINE STUDIES
NO plays a key role in innate immunity and host defense aga-
inst mycobacteria (1,2,7,43). For example, iNOS KO and im-
munodeficient mice infected with MTB are at a significantly 
higher risk of dissemination and mortality as compared with 
control mice (1,43). In addition, macrophages from mice with 
the  Bcg/natural  resistance  associated  macrophage  protein-1 
resistance  phenotype  show  inhibition  of  MTB  survival 
through NO production (3,44). Mycobacterial species exhibit 
variations in susceptibility to NO and its RNIs. For example, 
murine macrophages have been shown to inhibit the intra-
cellular  growth  of  M.  leprae, M .  b o v i s ,  and  MTB  H37Rv 
(7,11,17,45).  When  IFN-γ -treated  rat  alveolar  macrophages 
were  infected  with  M.  avium,  the  growth  of  the  bacterium 
was significantly inhibited by NO synthesized from L-arginine 
(46). 
    Contrasting data have been reported in murine and human 
macrophages infected with M. avium (6); neither competitive 
inhibition by L-NMMA nor depletion of L-arginine by arginase 
had any effect on M. avium growth in murine peritoneal mac-
rophages  or  human  monocyte-derived  macrophages  (6).  In 
addition, no significant inhibitory effects of NO produced by 
rat macrophages were observed on the growth of M. intra-
cellulare ( 4 5 ) .  I n  m u r i n e  m o d e l s  o f  l a t e n t  i n f e c t i o n ,  b o t h  
NO-dependent (iNOS- and IFN-γ -dependent antimycobacteri-
al mechanisms) and -independent (CD4
＋ T cells required for 
preventing reactivation of the disease) mechanisms maintain 
latent TB (4,47); however, the applicability of these reports 
to  humans  is  uncertain.
THE ROLE OF NO IN MYCOBACTERIAL 
INFECTION: HUMAN STUDIES
In contrast to the murine model of TB, there is controversy 
surrounding  the  role  of  NO  in  the  killing  and  inhibition  of 
M T B  i n  h u m a n s  ( 5 ) .  T h e  e a r l y  i n h i b i t i o n  o f  m y c o b a c t e r i a l  
growth by human alveolar macrophages has been shown to 
be NO-independent (48). Specifically, exogenous IFN-γ  fai-
led  to  produce  mycobactericidal  effects  in  human  alveolar 
macrophages (48). Nevertheless, a growing body of evidence 
suggests that NO production by MTB-infected human mono-
cytes/macrophages, macrophage-like cell lines, and epithelial 
cells  induces  mycobacteriostatic  activity  against  MTB  (16, 
49-52). For example, alveolar macrophages from healthy con-
trol  subjects  infected  with  MTB  produce  NO,  and  this  pro-
duction is correlated with the intracellular inhibition of MTB 
growth  (51).  One  study  demonstrated  increased  NO  pro-
duction in TB patients as compared with healthy controls fol-
lowing  the  infection  of  peripheral  blood  mononuclear  cells 
( P B M C ) s  w i t h  M T B  ( 5 0 ) .  O t h e r  s t u d i e s  h a v e  a l s o  d e m o n -
strated that alveolar macrophages are able to kill mycobac-
teria and that these antimycobacterial activities are dependent Nitric Oxide in Mycobacterial Infection
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o n  i N O S  e x p r e s s i o n  ( 4 9 , 5 3 ) .  T h e s e  r e s u l t s  s u g g e s t  a  s i g -
nificant  role  for  NO  in  host  defense  against  mycobacterial 
infection. Moreover, increased iNOS expression and pulmo-
nary NO production have been reported in alveolar macro-
p h a g e s  a n d  P B M C s  f r o m  T B  p a t i e n t s  a s  c o m p a r e d  w i t h  
healthy controls (8,10,16,54). In those studies, NO played a 
role  in  the  enhancement  of  TNF-α  a n d  I L - 1 β  s e c r e t i o n ,  
which  subsequently  affected  NO  production  via  feedback 
loops (8). These data indicate an autoregulatory role for NO. 
It has also been shown that iNOS and nitrotyrosine (a tissue 
m a r k e r  o f  N O  m e t a b o l i s m )  a r e  e x p r e s s e d  i n  m a c r o p h a g e s  
within  granulomatas  and  areas  of  TB  pneumonitis  (15,55). 
Human  PBMCs  and  bronchial  epithelial  cells  may  produce 
NO when stimulated with MTB-produced NO (50). In addi-
tion,  the  avirulent  strain  H37Ra  was  shown  to  induce  sig-
nificantly higher levels of NO production as compared with 
the virulent strain H37Rv (50). Recent studies have shown that 
L-arginine  depletion  induces  the  down-regulation  of  CD3ζ , 
thereby  impairing  T  cell  signaling,  whereas  the  addition  of 
L-arginine leads to CD3ζ  re-expression and the recovery of 
T cell proliferation (18,56). In addition, T cells from TB pa-
tients  show  reduced  CD3ζ  e x p r e s s i o n ,  w h i c h  i s  c o r r e l a t e d  
with arginase-induced L-arginine deficiency. These expression 
levels  were  normalized  with  successful  TB  treatment  (21). 
Taken together, these data suggest that NO plays a contrib-
utory  role  in  human  host  defense  against  MTB  infection.
THE ROLE OF NO IN MYCOBACTERIAL INFECTION 
OF THE CENTRAL NERVOUS SYSTEM (CNS)
The roles of NO and iNOS in host defense against infection 
of the CNS by intracellular pathogens have been reported in 
previous  studies  of  several  intracellular  pathogens  (e.g., 
Toxoplasma gondii and Sindbis virus) (57,58). The role of mi-
croglial  cells  in  neuropathogenesis  following  CNS  infection 
has  been  a  topic  of  growing  research  interest  (59).  It  was 
previously reported that in contrast to astrocytes, iNOS was 
not  expressed  in  human  microglia  following  stimulation  by 
IL-1β  or IFN- γ  (9,60). These findings suggest that NO and 
iNOS expression may be dependent on cell type and species. 
Indeed, previous reports demonstrated NO production in acti-
vated  murine  microglia,  but  not  in  human  microglia  (61). 
Recently,  significant  effort  has  been  devoted  to  developing 
appropriate models of TB infection in the CNS (CNS-TB) us-
ing rabbits or mice. Intracerebral inoculation with MTB or M. 
bovis BCG resulted in mononuclear cell infiltration, microglial 
cell  activation,  and  an  increase  in  the  number  of  bacterial 
cells within the CNS in a mouse model (62,63). In addition, 
inoculation with MTB or M. bovis BCG led to the up-regu-
lation of IL-1β , TNF-α , IL-6, and IFN-γ  within the CNS (63). 
Recently, Michael et al. (64) reported that iNOS KO mice in-
fected  intracerebrally  with  MTB  developed  clinical  manifes-
tations of CNS-TB, including high mortality rates and histo-
pathological  abnormalities  resembling  human  tuberculous 
meningitis throughout the meninges. The above clinical mani-
festations were absent in WT mice. These studies underscore 
the  importance  of  NO  in  defense  against  CNS-TB.
THE ROLE OF NO IN THE MYCOBACTERIAL 
INFECTION OF EPITHELIAL CELLS
Alveolar epithelial cells are able to actively participate in the 
pathogenesis of pulmonary inflammatory diseases by produc-
ing several cytokines and chemokines (65-67). Alveolar epi-
thelial cells produce NO and various innate immune effectors 
including chemokines (IL-8), which regulate immune activa-
tion. In addition, normal T cells express and secrete RANTES 
in response to MTB infection (19,67). Strong NO production 
via iNOS also occurs in human lung epithelial cells (19,66); 
however, the amount of NO released in response to MTB is 
not mycobactericidal (65,66). Various cytokines (IFN-γ , TNF-
α ,  and  IL-1β ;  alone  or  in  combination)  and  mycobacterial 
components stimulate MTB-infected epithelial cells, inducing 
NO  production  and  mycobactericidal  effects  (65,66).  These 
factors may contribute to innate immune control in epithelial 
cells  against  intracellular  pathogens  such  as  MTB.
CONCLUDING REMARKS
NO is a nonspecific, chemically reactive molecule that is im-
portant  in  host  defense  against  a  wide  variety  of  microbial 
pathogens.  However,  it  is  becoming  increasingly  clear  that 
specific killing mechanisms and cell types are not sufficient 
to kill mycobacteria in vivo. Although NO is not required for 
mycobactericidal activity in mouse models, the lack of a role 
for NO or its products (e.g., ONOO
−) has not been defini-
tively proven in humans. Nevertheless, a substantial body of 
evidence  indicates  a  role  for  NO  in  human  host  defenses 
against MTB. Additional studies are necessary to define the 
role of NO in relevant human cells including alveolar macro-
phages, microglia, and epithelial cells. Additionally, it would 
be useful to generate conditions that mimic in vivo environ-Nitric Oxide in Mycobacterial Infection
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ments, such as the co-culture of relevant cells. Such studies, 
which  will  refine  our  understanding  of  the  importance and 
s p e c i f i c  r o l e  o f  N O  i n  T B  d e f e n s e ,  m a y  l e a d  t o  i n n o v a t i v e  
strategies  for  TB  treatment.
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